Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $25.50 Average Target Price from Brokerages

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) have been assigned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $25.50.

A number of analysts have recently weighed in on the company. Guggenheim reiterated a “buy” rating on shares of Verve Therapeutics in a research report on Tuesday, March 25th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Verve Therapeutics in a report on Tuesday, March 25th. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Royal Bank of Canada decreased their price target on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th.

Verve Therapeutics Trading Down 1.1 %

Shares of NASDAQ VERV opened at $5.22 on Tuesday. Verve Therapeutics has a twelve month low of $4.31 and a twelve month high of $13.24. The business has a 50 day simple moving average of $6.94 and a 200-day simple moving average of $6.08. The company has a market capitalization of $463.52 million, a price-to-earnings ratio of -2.12 and a beta of 1.77.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, equities analysts predict that Verve Therapeutics will post -2.49 earnings per share for the current year.

Institutional Trading of Verve Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC grew its holdings in shares of Verve Therapeutics by 139.8% in the 3rd quarter. Barclays PLC now owns 222,919 shares of the company’s stock worth $1,079,000 after acquiring an additional 129,944 shares during the last quarter. State Street Corp lifted its holdings in shares of Verve Therapeutics by 27.0% in the third quarter. State Street Corp now owns 4,253,217 shares of the company’s stock valued at $20,586,000 after purchasing an additional 903,809 shares in the last quarter. Braidwell LP acquired a new stake in shares of Verve Therapeutics in the third quarter worth $3,020,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Verve Therapeutics by 28.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 572,173 shares of the company’s stock valued at $2,769,000 after buying an additional 126,110 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Verve Therapeutics by 465.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company’s stock valued at $241,000 after buying an additional 35,214 shares during the period. 97.11% of the stock is currently owned by institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.